Quantum BioPharma Partners with BitGo to Securely Store its Crypto Currency Assets

In This Article:

Quantum BioPharma
Quantum BioPharma

TORONTO, May 21, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today announced that it has selected BitGo Trust Company (“BitGo”) as one of its partners to securely manage and store its Bitcoin, Solana, XRP and DOGE coin holdings (“crypto currency assets”).

BitGo, known for its secure and compliant custody solutions, will provide institutional-grade custody services using its security infrastructure.

"We are pleased to partner with BitGo as our trusted custodian for our crypto currency assets," said Zeeshan Saeed, CEO and Executive Co-Chairman at Quantum. "As we expand our engagement with crypto currency assets, having a secure custodian like BitGo supports our security and compliance priorities as a public company."

BitGo offers a full suite of custody solutions, including multi-signature wallets and 100% cold storage technology, providing protection against theft, loss, or unauthorized access. Additionally, its insurance policy provides an added layer of security, aligning with Quantum’s standards for asset management.

“Institutions like Quantum are shaping the next generation of digital finance, and they deserve a foundation that’s built to last," said Mike Belshe, CEO of BitGo. "BitGo’s mission has always been to provide that backbone—secure, compliant, and trusted by the world’s leading firms.”

About Quantum BioPharma Ltd.

Quantum BioPharma (NASDAQ: QNTM) is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (“Lucid”), Quantum BioPharma is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum BioPharma invented unbuzzd™ and spun out its OTC version to a company, Celly Nutrition Corp. (“Celly Nutrition”), led by industry veterans. Quantum BioPharma retains ownership of 22.95% (as of December 31, 2024) of Celly Nutrition at www.unbuzzd.com. The agreement with Celly Nutrition also includes royalty payments of 7% of sales from unbuzzd™ until payments to Quantum BioPharma total $250 million. Once $250 million is reached, the royalty drops to 3% in perpetuity. Quantum BioPharma retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses. Quantum BioPharma maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represents loans secured by residential or commercial property.